Pirate primates in uncharted waters: Lymphocyte transfers in unrelated, MHC-matched macaques

Current HIV Research

Volumn 7, Issue 1, 2009, Pages 51-56

  Burwitz, Benjamin J ^a   Greene, Justin M ^a   O'Connor, David H ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD3 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ACUTE PHASE RESPONSE; ADOPTIVE TRANSFER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; FRIEND LEUKEMIA VIRUS; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE TRANSFER; MACACA; MEDICAL RESEARCH; MONKEY DISEASE; NONHUMAN; PATHOGENESIS; PRIMATE; RETROVIRUS; REVIEW; SPECIES DIFFERENCE; SPLEEN FOCUS FORMING VIRUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; ANIMAL; IMMUNOLOGY; LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS;

ADOPTIVE TRANSFER; ANIMALS; LYMPHOCYTES; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 59649098048     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209787048492     Document Type: Review

References (53)

1. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205: 7-12.
2. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine? N Engl J Med 2007; 357: 2653-5.
3. Yang OO. Retracing our STEP towards a successful CTL-based HIV-1 vaccine. Vaccine 2008: 26(25): 3138-41.
4. Lawler SH, Sussman RW, Taylor LL. Mitochondrial DNA of the Mauritian macaques (Macaca fascicularis): an example of the founder effect. Am J Phys Anthropol 1995; 96: 133-41.
5. Wiseman RW, Wojcechowskyj JA, Greene JM, et al. Simian immunodeficiency virus SIVmac239 Infection of major histocompatibility complex-identical cynomolgus macaques from mauritius. J Virol 2007; 81: 349-61.
6. Dittmer U, Brooks DM, Hasenkrug KJ. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol 1998; 72: 6554-8.
7. Dittmer U, Brooks DM, Hasenkrug KJ. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med 1999; 5: 189-93.
8. Dittmer U, Brooks DM, Hasenkrug KJ. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J Virol 1999; 73: 3753-7.
9. Dittmer U, Hasenkrug KJ. Different immunological requirements for protection against acute versus persistent Friend retrovirus infections. Virology 2000; 272: 177-82.
10. Dittmer U, Hasenkrug KJ. Cellular and molecular mechanisms of vaccine-induced protection against retroviral infections. Curr Mol Med 2001; 1: 431-6.
11. Dittmer U, He H, Messer RJ, et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 2004; 20: 293-303.
12. Dittmer U, Race B, Hasenkrug KJ. Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus. J Virol 1999; 73: 8435-40.
13. Hasenkrug KJ. CD4+ regulatory T cells in chronic viral infection. Novartis Found Symp 2003; 252: 194-9; discussion 199-210.
14. Hasenkrug KJ, Dittmer U. Immune control and prevention of chronic Friend retrovirus infection. Front Biosci 2007; 12: 1544-51.
15. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-41.
16. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 1996; 219: 195-205.
17. Sernicola L, Corrias F, Koanga-Mogtomo ML, et al. Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. Virology 1999; 256: 291-302.
18. Stebbings R, Berry N, Stott J, et al. Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology 2004; 330: 249-60.
19. Titti F, Sernicola L, Geraci A, et al. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 1997; 78: 2529-39.
20. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73: 8356-63.
21. Johnson RP, Lifson JD, Czajak SC, et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999; 73: 4952-61.
22. Connor RI, Montefiori DC, Binley JM, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998; 72: 7501-9.
23. Bernstein WB, Cox JH, Aronson NE, et al. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons. Clin Immunol 2004; 111: 262-74.
24. Hoffmann C, Stellbrink HJ, Dielschneider T, et al. Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis. Br J Haematol 2007; 136: 641-8.
25. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002; 8: 47-53.
26. Walker R, Blaese RM, Carter CS, et al. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. Hum Gene Ther 1993; 4: 659-80.
27. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-93.
28. Valdez H. Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev 2002; 4: 157-64.
29. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-66.
30. Bex F, Hermans P, Sprecher S, et al. Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. Blood 1994; 84: 3317-26.
31. Bobisse S, Zanovello P, Rosato A. T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. Expert Opin Biol Ther 2007; 7: 893-906.
32. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999; 5: 34-41.
33. Joseph A, Zheng JH, Follenzi A, et al. Lentiviral vectors encoding HIV-1-specific TCR genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T Lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008; 82(6): 3078-89.
34. Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1: 330-6.
35. McKinney DM, Lewinsohn DA, Riddell SR, Greenberg PD, Mosier DE. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. J Immunol 1999; 163: 861-7.
36. Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999; 93: 1506-10.
37. Clay CC, Rodrigues DS, Brignolo LL, et al. Chemokine networks and in vivo T-lymphocyte trafficking in nonhuman primates. J Immunol Methods 2004; 293: 23-42.
38. Clay CC, Rodrigues DS, Harvey DJ, Leutenegger CM, Esser U. Distinct chemokine triggers and in vivo migratory paths of fluorescein dye-labeled T Lymphocytes in acutely simian immunodeficiency virus SIVmac251-infected and uninfected macaques. J Virol 2005; 79: 13759-68.
39. Chea S, Dale CJ, De Rose R, Ramshaw IA, Kent SJ. Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol 2005; 79: 3748-57.
40. Villinger F, Brice GT, Mayne AE, et al. Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 2002; 99: 590-9.
41. Onlamoon N, Plagman N, Rogers KA, et al. Anti-CD3/28 mediated expansion of macaque CD4+ T cells is polyclonal and provides extended survival after adoptive transfer. J Med Primatol 2007; 36: 206-18.
42. Loffredo JT, Burwitz BJ, Rakasz EG, et al. The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape. J Virol 2007; 81: 2624-34.
43. Loffredo JT, Rakasz EG, Giraldo JP, et al. Tat(28-35)SL8-specific CD8+ T lymphocytes are more effective than Gag(181-189)CM9-specific CD8+ T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J Virol 2005; 79: 14986-91.
44. Sacha JB, Chung C, Rakasz EG, et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178: 2746-54.
45. Sacha JB, Chung C, Reed J, et al. Pol-specific CD8+ T cells recognize SIV-infected cells prior to Nef-mediated major histocompatibility complex class I down-regulation. J Virol 2007; 81(21): 11703-12.
46. Allen TM, Mortara L, Mothe BR, et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76: 4108-12.
47. Gallimore A, Cranage M, Cook N, et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995; 1: 1167-73.
48. Greene JM, Burwitz BJ, Blasky AJ, et al. Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques. PLoS ONE (In Press).
49. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol 1998; 72: 6646-56.
50. Mattapallil JJ, Smit-McBride Z, Dailey P, Dandekar S. Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2. J Virol 1999; 73: 6661-9.
51. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527-38.
52. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447-50.
53. Wilson JD, Imami N, Watkins A, et al. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000; 182: 792-8